The Outcome of Six Patients with COVID-19 Infection and Multiple Myeloma. A Case Series and Literature Review COVID-19 in Multiple Myeloma patients

Main Article Content

Hesham Elsabah
Mahmood B. Aldabt
Ruba Taha
Dina Sameh Soliman
Halima Elomri
Feryal Ibrahim
(*) Corresponding Author:

Abstract

No abstract, as A letter to the Editor.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

References

References
1. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on February 12, 2020).
2. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91-95. doi:10.1016/j.ijid.2020.03.017
3. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China [published online ahead of print, 2020 Mar 25]. JAMA Oncol. 2020;6(7):1108-1110. doi:10.1001/jamaoncol.2020.0980
4. El-Sharkawi D, Iyengar S. Haematological cancers and the risk of severe COVID-19: Exploration and critical evaluation of the evidence to date [published online ahead of print, 2020 Jun 19]. Br J Haematol. 2020;10.1111/bjh.16956. doi:10.1111/bjh.16956
5. Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107-113. doi:10.3324/haematol.2014.107714
6. Dhakal, B., D’Souza, A., Chhabra, S. et al. Multiple myeloma and COVID-19 Leukemia. (2020) 34:1961–1963 https://doi.org/10.1038/s41375-020-0879-9
7. K Gadó , G Domján, H Hegyesi. ROLE OF INTERLEUKIN-6 IN THE PATHOGENESIS OF MULTIPLE MYELOM. Cell Biology International Volume 24, Issue 4, April 2000, Pages 195-209
8. Pan Luo | Yi Liu | Lin Qiu | Xiulan Liu | Dong Liu | Juan Li .Tocilizumab treatment in COVID?19: A single center experience J Med Virol. 2020,92:814-818.DOI: 10.1002/jmv.25801

9. Giovanni Guaraldi*, Marianna Meschiari*, Alessandro Cozzi-Lepri, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The lancet.com/rheumatology. 2020 , Vol 2,issue 8,E474-E484

10. A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) ClinicalTrials.gov Identifier: NCT04320615

11. Hoffman-La Roche. A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia (REMDACTA). June 2020. Available at https://clinicaltrials.gov/ct2/show/NCT04409262. Accessed on June 1, 2020.

12. Genentech. A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants with COVID-19 Pneumonia. May 2020. Available at https://clinicaltrials.gov/ct2/show/NCT04372186. Accessed on May 18, 2020.

13. Zhang X, Song K, Tong F, et al. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 2020;4(7):1307-1310.

14. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19(6):102537. doi:10.1016/j.autrev.2020.102537